

Medical Device White Paper Series

# Medical device clinical investigations – What's new under the MDR?

Author – Maria Donawa, President, Donawa Lifescience



Disclaimer – This white paper is issued for information only. It does not constitute an official or agreed position of BSI Standards Ltd. The views expressed are entirely those of the authors. All rights reserved. Copyright subsists in all BSI publications including, but not limited to, this white paper. Except as permitted under the Copyright, Designs and Patents Act 1988, no extract may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic, photocopying, recording or otherwise – without prior written permission from BSI. While every care has been taken in developing and compiling this publication, BSI accepts no liability for any loss or damage caused, arising directly or indirectly in connection with reliance on its contents except to the extent that such liability may not be excluded in law.

## Introduction

---

This paper discusses important new requirements for pre-market and post-market clinical investigations under the European Medical Device Regulation (2017/745) (MDR). It also addresses the importance of defining the regulatory purpose of a study, the relationship of a clinical investigation with quality management system (QMS) practices and strategies for conducting a successful clinical investigation, including the importance of defining the steps for its planning and conduct. Some of these steps can be carried out in parallel, while others will need to be sequentially followed. Knowing which ones can overlap will benefit the project and its timelines.

The conduct of a clinical investigation – also referred to as a clinical study in this paper – is one of the most time consuming and resource intensive activities that a medical device manufacturer can face. For these reasons, manufacturers should ensure that the purpose of the clinical investigation is clear; all applicable regulations, common specifications (e.g. concerning device-specific requirements relevant for clinical investigations), international standards, European guidance documents and national guidance documents have been identified; all persons involved with the study understand their roles and responsibilities; and the study is well organized and conducted in accordance with relevant QMS practices.



The clinical investigations discussed in this paper are generally conducted to meet regulatory requirements related to the generation of clinical data in support of safety and/or clinical performance for CE marking or maintaining the CE mark of the subject device. More than one clinical investigation may be needed. For this reason, manufacturers should clearly define the regulatory purpose for generating such data and identify the clinical development stage during which the clinical study is to be conducted.

MDR Article 10(9) requires manufacturers of devices, other than investigational devices, to establish a QMS that ensures compliance with the MDR and that addresses among other aspects, product realization, including planning, design, development, production and service provision. Clinical investigations are, in most cases, part of the design process and, where PMCF investigations are conducted, intended to demonstrate ongoing device safety and clinical performance requirements. Thus, clinical investigations are activities that should be managed under the QMS in that they are generally intended to meet the requirements of the MDR.

The development of key standard operating procedures (SOPs) for managing the clinical investigation process, within the QMS, serves the same purpose as SOPs developed for other aspects of a manufacturer's processes. They provide clarity, consistency, and a means for avoiding errors and omissions. They will also facilitate the management of clinical investigations conducted under the Medical Devices Directive (93/42/EEC) (MDD) or Active Implantable Medical Device Directive (90/385/EEC) (AIMDD), but continuing under the Medical Device Regulation (2017/745) (MDR), or those that will be conducted solely under the MDR.

SOPs for managing the clinical investigation process are applicable not only to manufacturers deciding to manage clinical investigations internally with company personnel, but also to those that need to outsource one or more clinical investigation activity to an external vendor. In the latter case, fewer internal SOPs may be needed if the SOPs of the external vendor are used.

The availability of persons who understand the medical device clinical investigation process, whether by training, experience or both, is critical for its successful implementation. In contrast, assigning persons with little or no experience or knowledge of clinical investigation requirements and management is associated with ineffective study management, which can lead to project delays, and possibly, failure to achieve intended clinical data objectives.

## MDR requirements for pre-market clinical investigations

### General considerations

---

MDR article 2(45) defines 'clinical investigation' as:

'any systematic investigation involving one or more human subjects, undertaken to assess the safety or performance of a device.'

A pre-market clinical investigation, namely, a clinical investigation with a device that has not yet been CE marked, will need to comply with the MDD, AIMDD, or the MDR. When clinical investigations are conducted under the MDR, they will also need to comply with any applicable common specifications, defined in MDR Article 2(71) as:

'a set of technical and/or clinical requirements, other than a standard, that provides a means of complying with the legal obligations applicable to a device, process or system.'

A clinical investigation will also need to comply with any applicable requirements of the national competent authority/authorities and ethics committee(s). Applicable European harmonized standards should be followed and other relevant international standards and European and national guidance documents should be taken into consideration. It is also important that sponsors are fully versed in the state of the art in medical practice related to the device technology involved, including relevant practice guidelines or other device-related guidance. This is important because the demonstration of compliance of a device with MDR safety and clinical performance requirements, for example, those specified in general safety and performance requirement (GSPR 1), must take account of the generally acknowledged state of the art.

The MDR sets out very detailed requirements regarding clinical investigations in comparison with the Directives. MDR Articles 62 through 80 address:

- general requirements regarding clinical investigations conducted to demonstrate conformity of devices
- informed consent
- clinical investigations on subjects requiring special consideration
- application process and assessment by Member States
- conduct of the clinical investigation
- electronic system on clinical investigations and other aspects



Implementing acts by the European Commission, intended to provide additional details, are covered in MDR Article 81. MDR Annex XV, Clinical Investigations, consists of three chapters: Chapter 1, General Requirements; Chapter 2, Documentation Regarding the Application for Clinical Investigation; and Chapter 3, Other Obligations of the Sponsor. The AIMDD and MDD each specify requirements regarding clinical investigations in only one article (AIMDD Article 10 and MDD Article 15), and parts of two annexes (AIMDD Annexes 6 and 7 and MDD Annexes VIII and X).

In spite of the detailed requirements included in the MDR, manufacturers with experience in conducting clinical investigations may find that many of these requirements are familiar. This is because similar requirements and procedures are described in the European harmonized standard, BS EN ISO 14155:2011, Clinical investigation of medical devices for human subjects – Good clinical practice, and in various European guidance documents related to clinical investigation. The European guidance documents are:

- MEDDEV 2.7/4 on the need for, and general principles of, clinical investigations
- MEDDEV 2.7/2 Rev 2 on clinical investigation validation and assessment by competent authorities
- MEDDEV 2.7/3 Rev. 3 on serious adverse event (SAE) reporting

In fact, the requirements in the MDR regarding clinical investigations were intentionally based on BS EN ISO 14155:2011 (see MDR 'Whereas' statement #64) and on the European guidance documents listed above.

It is important to note that BS EN ISO 14155:2011 has been revised. During its revision every effort was made to avoid conflicts with the MDR, while meeting international needs. At the time of writing of this paper, the revised standard is expected to be published in June or July 2020 and in future become a European harmonized standard regarding compliance with MDR clinical investigation requirements. Due to a delay in the harmonization process however, it is not possible to predict the timing of harmonization.

Regardless of its harmonization status, manufacturers are advised to purchase the standard as soon as it is available and implement all applicable procedures and practices, as it will reflect the state of the art regarding good clinical practice (GCP) for medical device clinical investigations. Any references made in this paper to the revised standard apply to the Final Draft of ISO/FDIS 14155 in which only editorial changes can be made before publication of the final standard.

The European Commission is in the process of issuing guidance documents to aid in complying with the MDR, including clinical investigation requirements, as discussed below, which will be available on the European Commission website.

## New requirements under the MDR

---

The MDR introduces new requirements, which need to be carefully reviewed and addressed in applicable procedures for the conduct of clinical investigations under the MDR. The new MDR requirements presented here are those that will most likely require changes in the conduct of a clinical investigation even if BS EN ISO 14155:2011 and European clinical investigation-related guidance documents have been followed.



## Introduction of 'sponsor'

The MDR has introduced the term 'sponsor', defining it in MDR Article 2(49), as:

*'any individual, company, institution or organisation which takes responsibility for the initiation, for the management and setting up of the financing of the clinical investigation.'*

This is important, because under the Directives, only the manufacturer or authorized representative is identified as the responsible party for the conduct of a clinical investigation. This has resulted in some uncertainty regarding the regulatory responsibility of an independent clinical investigator who initiates a medical device clinical investigation.

Under the MDR, the definition of 'sponsor' means that clinical investigators initiating clinical studies will be responsible for meeting MDR clinical study-related requirements. However, this does not prevent agreements on study conduct between investigators and manufacturers. It will be useful, however, for manufacturers intending to support the study or use the study results for regulatory purposes, to ensure that the investigator acting as a study sponsor is aware of sponsor-related requirements under the MDR.

## Legal representative

Under MDR Article 62, General requirements regarding clinical investigations conducted to demonstrate conformity of devices, a legal representative must be designated when the sponsor of a clinical investigation to be conducted in the European Union (EU) is not in the EU. The legal representative will be responsible for ensuring compliance with the sponsor's obligations. The MDR allows, however, a Member State the option of not applying this requirement if the study is conducted only in the territory of the Member State. Unless exempted, this is an important new requirement that a non-EU sponsor conducting a clinical investigation in the EU will need to address.

## Ethics committees

The responsibility of ethics committees is to evaluate a clinical investigation and determine whether ethical principles are being met. Requirements related to ethics committee composition and function are not specified in the AIMDD or MDD, nor in the MDR – however, MDR Article 62(3) requires that ethical review of a clinical investigation must be performed by an ethics committee in accordance with national law. The MDR also requires that Member States must ensure that the procedures for review by ethics committees are compatible with the procedures set out in the MDR and that at least one lay person must participate in the ethical review.

Thus, the ethics committee approval process is not harmonized, which has led to variability in ethics committee procedures and required documents within the same country and among different countries. The specific ethics committee that is required for approving a study also varies.

Approval timelines range from 30 to 90 days or more in some cases.

To avoid delays in ethics committee approval, sponsors should not simply leave this process to the investigator without ensuring that all submission requirements will be met. This means that sponsors or if outsourced, the selected contract research organization (CRO), should:

- understand the regulatory category of the study (i.e. pre-market, post-market) and type of study (registry, observational, interventional, other)
- be informed about the procedural and documentation requirements of each ethics committee
- understand the need for a signed site contract
- determine whether translations are needed
- determine who must sign which document

## Competent authority approval

The responsibility of competent authorities is to evaluate a clinical investigation application and determine whether regulatory requirements are being met. MDR Article 70, Application for clinical investigations, specifies the steps in the application process with specific time periods that must be respected. For example, Article 70(2) requires that within one week of making any change, the sponsor must update any change in the submitted documentation.

According to Article 70(5), the date that the Member State notifies the sponsor that the application is complete is considered the validation date of the application. Article 70(6) provides that during the period when the application is being assessed, the Member State may request additional information from the sponsor.

Article 70(7) specifies that clinical investigations with class I or non-invasive class IIa and class IIb devices may be initiated immediately after the validation date unless otherwise stated by national law, provided that a negative opinion valid for the entire Member State has not been issued by the applicable ethics committee.

For devices other than class I or non-invasive class IIa and class IIb devices, the clinical investigation may be initiated as soon as the Member State has notified the sponsor that the investigation has been authorized. This must be within 45 days of the validation date, although the Member State may extend this by 20 days for the purpose of consulting with experts.

As stated previously, MDR Annex XV, Chapter II, lists the documentation that must be included in the clinical investigation application. It is also possible that national competent authorities may request additional documentation, which is important to address during clinical investigation planning to avoid delays during the application process.



### Inspection of investigation sites

MDR Article 72(5) introduces the requirement that Member States inspect, at an appropriate level, investigation site(s) to check that clinical investigations are conducted in accordance with the requirements of the MDR and the clinical investigation plan (CIP). This means that sponsors should ensure that the relevant investigation site involved in the conduct of a clinical investigation with the sponsor's medical device is adequately prepared for such an inspection. The areas inspected will depend upon the practices and procedures of the Member States.

### Procedures for immediate identification or recall

MDR Article 72(6) introduces a new requirement, which requires that the sponsor establishes a procedure for emergency situations which enables the immediate identification and, where necessary, an immediate recall of the devices used in the clinical investigation. It is expected that this procedure will be managed within the manufacturer's QMS.



## Coordinated assessment procedure for clinical investigations

MDR Article 78, *Coordinated assessment procedure for clinical investigations*, introduces a new process for submitting a clinical investigation application where the investigation is planned to be conducted in more than one Member State. The sponsor may submit a single application, transmitted by means of the electronic system referred to in MDR Article 73, to all Member States in which the investigation is to be conducted. The sponsor must propose that one of the Member States acts as the coordinating Member State. Initially, this procedure will involve only Member States voluntarily agreeing to apply the procedure. It becomes mandatory, however, on 27 May 2027, unless this date changes as a result of a review that must be conducted by the European Commission by 26 May 2026.

## SAE reporting to Member States

Under MDR Article 80, Recording and reporting of adverse events that occur during clinical investigations, paragraph 2 states:

The sponsor shall report, without delay to all Member States in which the clinical investigation is being conducted, all of the following by means of the electronic system referred to in Article 73:

- (a) any serious adverse event that has a causal relationship with the investigational device, the comparator or the investigation procedure or where such causal relationship is reasonably possible;
- (b) any device deficiency that might have led to a serious adverse event if appropriate action had not been taken, intervention had not occurred, or circumstances had been less fortunate;
- (c) any new findings in relation to any event referred to in points (a) and (b).'

The need to report only SAEs with a causal relationship with the investigational device, comparator or investigation procedure is an important difference from the AIMDD and MDD, which require that all SAEs be immediately notified to all competent authorities of the Member States in which the clinical investigation is being performed.

It should also be noted that MDR Article 120(11) states:

'Clinical investigations which have started to be conducted in accordance with Article 10 of Directive 90/385/EEC or Article 15 of Directive 93/42/EEC prior to 26 May 2021 may continue to be conducted. As of 26 May 2021, however, the reporting of serious adverse events and device deficiencies shall be carried out in accordance with this Regulation.'

A guidance on safety reporting under the MDR has been developed by the Clinical Investigation and Evaluation (CIE) subgroup of the Medical Device Coordination Group (MDCG). The CIE assists the MDCG on issues relating to clinical investigation and evaluation of medical devices in accordance with the MDR. The guidance, which is an update on MEDDEV 2.7/3 Rev. 3, addresses various issues including safety reporting of clinical studies that have begun under the Directives, how safety reports should be submitted to National Competent Authorities in the absence of Eudamed (the delay in Eudamed implementation is discussed later), and other issues. The guidance document Safety reporting in clinical investigations of medical devices under the Regulation (EU) 2017/745 (MDCG 2020-10/1) and Clinical Investigation Summary Safety Report Form v1.0 (MDCG 2020-10/2) are available on the European Commission website.



## Monitoring

MDR Article 72(2), Conduct of a clinical investigation, states the following:

'In order to verify that the rights, safety and well-being of subjects are protected, that the reported data are reliable and robust, and that the conduct of the clinical investigation is in compliance with the requirements of this Regulation, the sponsor shall ensure adequate monitoring of the conduct of a clinical investigation. The extent and nature of the monitoring shall be determined by the sponsor on the basis of an assessment that takes into consideration all characteristics of the clinical investigation including the following:

- (a) the objective and methodology of the clinical investigation; and
- (b) the degree of deviation of the intervention from normal clinical practice.'

This means that under the MDR, appropriate monitoring is a requirement and not an option.

## Independence of monitors

Monitors are appointed by sponsors to check on the progress of a clinical investigation to ensure that it is being conducted in compliance with the CIP, established GCPs and other applicable regulatory requirements.

There is an important new restriction regarding the appointment of monitors, which is specified in MDR Annex XV, Clinical investigations, Chapter III, Other Obligations of the Sponsor, Section 4, which states:

'The Sponsor shall appoint a monitor that is independent from the investigational site to ensure that the investigation is conducted in accordance with the CIP, the principles of good clinical practice and this Regulation.'

The CIP is the clinical investigation plan, which MDR Article 2(47) defines as:

'a document that describes the rationale, objectives, design, methodology, monitoring, statistical considerations, organisation and conduct of a clinical investigation.'

This is an important new requirement because some medical device clinical investigations have been monitored by persons who are employed by an investigational site or where a clinical investigator maintains a unit for monitoring a clinical study in which the investigator is involved. This new requirement means that sponsors conducting clinical investigations under the MDR will need to ensure that the monitor is not part of a unit within the clinical investigation site where the clinical investigation is being conducted.

### Prohibition of waivers

Annex XV, Clinical Investigations, Chapter II, Documentation Regarding the Application for Clinical Investigation, Section 3, specifies detailed requirements regarding the CIP. Section 3.10 indicates that the CIP must contain a:

'Policy regarding follow-up and management of any deviations from the CIP at the investigational site and clear prohibition of use of waivers from the CIP.'

The clear prohibition of use of waivers is the new requirement. Although the exercise of a waiver regarding some aspect of the CIP may not be a frequent occurrence, the sponsor of the clinical investigation needs to be aware of the prohibition of a waiver. That is, the sponsor should be particularly careful in developing a CIP that meets regulatory and data quality objectives but is not so stringent as to create unnecessary difficulties in compliance.

### GCP inspections by sponsors

MDR Annex XV, Chapter III, Section 6 requires that sponsors provide evidence that the clinical investigation is being conducted in line with GCPs, for instance through internal or external inspection. This requirement was not included in the Directives. Revised ISO 14155 includes Annex J (informative), 'Clinical investigation audits', which is a new annex that provides general guidance on the areas that can be covered in these inspections.

### Relationship between clinical investigation and clinical evaluation

As indicated previously, MDR Annex XIV, Part A, Section 1(a), last indent, requires that the clinical evaluation plan includes information on the clinical development plan, specifically:

'a clinical development plan indicating progression from exploratory investigations, such as first-in-man studies, feasibility and pilot studies, to confirmatory investigations, such as pivotal clinical investigations, and a PMCF as referred to in Part B of this Annex with an indication of milestones and a description of potential acceptance criteria'

Section 2.4, Chapter I of Annex XV, Clinical Investigation, requires clinical investigations to be in line with the clinical evaluation plan.

Section 1.5, Chapter II of Annex XV, requires that the clinical investigation application to include, among other information, *"details and/or reference to clinical evaluation plan."*

This means that clinical investigations must be consistent with the information contained in the clinical development plan, which is part of the clinical evaluation plan.

Section 3.6.1, Chapter II of Annex XV, requires the CIP to include, among other detailed information, 'type of investigation with rationale for choosing it, for its endpoints and for its variables as set out in the clinical evaluation plan.' Again, this means that the information contained in the CIP and the clinical evaluation plan must be consistent.

## MDR requirements for PMCF investigations

MDR Article 74, Clinical investigations regarding devices bearing the CE marking, refers to a post-market clinical follow-up (PMCF) investigation as a clinical investigation conducted to further assess, within the scope of its intended purpose, a device which already bears the CE marking.

Manufacturers should be careful to distinguish a PMCF investigation from other types of PMCF, some of which are referred to in MDR Annex XIV, Part B, Section 6.2, such as: gathering of clinical experience gained, feedback from users, screening of scientific literature and of other sources of clinical data, or evaluation of suitable registers. These types of PMCF are different from a PMCF investigation, which is subject to a series of requirements, specified in MDR Article 74, some of which are the same as those applicable to pre-market clinical investigations.

In seeking to comply with MDR Article 74, it is very important to determine whether the PMCF investigation is planned to be conducted exactly in accordance with standard practice and the device's instructions for use (IFU) or whether any additional procedures (e.g. additional blood analyses, diagnostic X-rays or scans, or other procedures) are planned and, if additional procedures are planned, whether they are invasive or could be considered burdensome. This is because MDR Article 74 specifies that where a PMCF investigation involves submitting subjects to procedures additional to those performed under normal conditions of use, and those additional procedures are invasive or burdensome, the sponsor must notify the Member States concerned at least 30 days before the study commences, by means of the electronic system referred to in MDR Article 73.

The sponsor of a PMCF investigation that involves additional procedures that are invasive or could be considered burdensome is also required to include documentation referred to in MDR Annex XV, Clinical Investigation, Chapter II, Documentation Regarding the Application for Clinical Investigation, as part of the notification. This documentation is the same type of documentation required for pre-market clinical investigations.



Revised ISO 14155 will include Annex I (informative), Clinical development stages, which is a new annex, that includes Section I.6, Burden to subjects. This section should be useful in considering factors that are important for complying with MDR Article 74. This is because this section provides information on the categorization of clinical investigations based on interference with normal clinical practice.

Regarding compliance with adverse event reporting, MDR Article 80(5) requires that in the case of PMCF investigations, the provisions on vigilance laid down in MDR Articles 87 to 90 and in the acts adopted pursuant to MDR Article 91 apply.

MDR Article 80(6), however, states the following:

'Notwithstanding paragraph 5, this Article shall apply where a causal relationship between the serious adverse event and the preceding investigational procedure has been established.'

By 'this Article shall apply', Article 80(6) is referring to MDR Article 80(1) through (4).

That is, manufacturers will need to determine whether a serious incident has occurred, which needs to be reported under MDR vigilance requirements as specified in MDR Articles 87 to 90 or whether a serious adverse event has occurred, which meets the requirements of Article 80(6) and needs to be recorded and reported as specified in Article 80(1) to (4).

## MDR requirements regarding other clinical investigations

MDR Article 82(1), Requirements regarding other clinical investigations, specifies that clinical investigations, not performed for any of the purposes listed in MDR Article 62(1), must comply with the provisions listed below.

- MDR Article 62, General requirements regarding clinical investigations conducted to demonstrate conformity of devices, specifically:
  - paragraph (2), which concerns the need for a sponsor not established in the EU to appoint a natural or legal person in the EU as its legal representative
  - paragraph (3), which requires that the rights, safety, dignity, and well-being of subjects be protected and that clinical investigations must be subject to scientific and ethical review.
- MDR Article 62(4), which lists the conditions that must be met to conduct a clinical investigation, specifically:
  - point (b), which requires that a negative opinion from an ethics committee, valid for the entire Member State, has not been issued
  - point (c), which specifies need for a sponsor, legal representative, or where relevant, contact person, to be in the EU
  - point (d), which requires protection of vulnerable populations in accordance with Articles 64 to 68
  - point (f), which specifies requirements for informed consent when the subject is unable to provide it

- point (h), which requires a safeguard of the rights subjects concerning their physical and mental integrity and of privacy and protection of data
- point (l), which requires that the investigational device conforms to applicable GSPRs
- MDR Article 62(6), which requires that the investigator has a profession recognized in the Member State concerned and that any other personnel involved in conducting the clinical investigation are appropriately qualified.

An example of such an investigation is a marketing study intended to identify user preferences that are not related to any of the purposes identified in MDR Article 62(1).

Furthermore, MDR Article 82(2) requires that to protect the rights, safety, dignity and well-being of subjects and the scientific and ethical integrity of clinical investigations not performed for any of the purposes listed in Article 62(1), each Member State shall define any additional requirements for such investigations, as appropriate for each Member State concerned.

This means that manufacturers should check on and comply with any national requirements that apply to the conduct of such types of clinical investigations.

## Eudamed

---

The Eudamed database will be extremely important in the implementation of the MDR and is intended to have many functions, including the registration of devices and economic operators, and the receipt of vigilance and field safety reports. It will also serve an important function regarding the fulfillment of MDR clinical investigation requirements.

Unfortunately, Eudamed will not be fully functional on the date of application of the MDR, which is now 26 May 2021, having been extended from 26 May 2020. The launch date is now planned for May 2022 to coincide with the date of application of the In Vitro Diagnostic Medical Devices Regulation (2017/746) (IVDR).

For this reason and until Eudamed becomes fully functional, MDR Article 123, Entry into force and date of application, Section 3(d), provides a derogation of the need to enter information into the Eudamed database, including information concerning clinical investigations. It is important that manufacturers carefully review this section of the MDR to understand which requirements are affected, so that they can be addressed in relevant procedures, which will require modification once Eudamed becomes fully functional.

As listed in Section 3(d), derogation of requirements related to clinical investigations and reporting of serious adverse events and serious incidents apply to the following:

- Articles 70 to 77
- Article 78(1) to (13)
- Articles 79 to 82
- Articles 87 and 88

- Article 89(5) and (7)
- Article 89(8), third subparagraph
- Article 90

In accordance with Section 3(d), the obligations and requirements related to Eudamed will apply six months after the date of publication of a notice in the *Official Journal of the European Union*, described in MDR Article 34, Functionality of Eudamed, indicating that Eudamed is fully functional. Until Eudamed is fully functional, the corresponding provisions of the AIMDD and MDD will apply.

## Regulatory purpose of clinical investigations

### Regulatory purpose of a pre-market clinical investigation

Pre-market clinical investigations are generally conducted to generate clinical data in support of safety and/or clinical performance for CE marking. They may also be conducted in stages as more than one investigation may be needed to generate the necessary clinical data. In this regard, MDR Annex XIV, Part A, Section 1(a), last indent, requires that the following be included in the clinical evaluation plan:

‘a clinical development plan indicating progression from exploratory investigations, such as first-in-man studies, feasibility and pilot studies, to confirmatory investigations, such as pivotal clinical investigations...’

Revised ISO 14155, Annex I (informative), ‘Clinical development stages’, describes the types of clinical investigations typically associated with different clinical stages and should prove to be useful in this determination.



In addition, the conduct of a clinical investigation for CE marking purposes is directly related to the requirements in MDR Article 61, Clinical evaluation. This is because Article 61 requires that confirmation of conformity with relevant GSPRs in MDR Annex I, the evaluation of undesirable side-effects, and the acceptability of the benefit-risk ratio referred to in Sections 1 and 8 of Annex I, must be based on clinical data providing sufficient clinical evidence. Sections 1 and 8 are also referred to as GSPRs 1 and 8.

GSPR 1 requires that devices achieve the performance intended by the manufacturer, are safe and effective, that any risks associated with device use are acceptable when weighed against the benefits to patients, and that the devices are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. GSPR 8 requires that all known and foreseeable risks, and any undesirable side-effects, be minimized and acceptable when weighed against the evaluated benefits to the patient and/or user arising from the achieved performance of the device during normal conditions of use.

Clinical data from a clinical investigation may be needed to clarify risks associated with the use of the device or to validate risk control measures, such as those related to the design, usability or information contained in the IFU.

In addition to GSPRs 1 and 8, the manufacturer will need to determine whether other GSPRs, for example, GSPR 5 related to use error, or other GSPRs, will require confirmation of conformity based on clinical data. Thus, the regulatory purpose of the clinical investigation for CE marking purposes is the generation of clinical data to satisfy identified GSPRs.

These determinations will have a direct effect on clinical investigation objectives and will need to be addressed carefully.

MDR Article 61(2) also provides an option that did not exist under the Directives, which applies to all class III devices and class IIb active devices intended to administer and/or remove a medicinal product, as referred to in MDR Annex VIII, Section 6.4 (Rule 12). This option allows a manufacturer to consult an expert panel, referred to in Article 106, Provision of scientific, technical and clinical opinions and advice, before the clinical evaluation and/or investigation. The purpose is for the expert panel to review the manufacturer's intended clinical development strategy and proposals for clinical investigation. The manufacturer must give due consideration to the views expressed by the expert panel and the consideration must be documented in the clinical evaluation report. A call for expression of interest to be appointed to MDR expert panels was published in 2019; however, it is not known at this time when set up will be complete and the panels will be functioning.

## Regulatory purpose of a PMCF investigation

---

The regulatory purpose for conducting a PMCF investigation can be one or more of the aims listed in MDR Annex XIV, Part B, Section 6.1. These aims include:

- confirming the safety and performance of the device throughout its expected lifetime
- identifying previously unknown side-effects and monitoring the identified side-effects and contraindications
- identifying and analyzing emergent risks on the basis of factual evidence
- ensuring the continued acceptability of the benefit-risk ratio referred to in Sections 1 and 8 of Annex I



- identifying possible systematic misuse or off-label use of the device, with a view to verifying that the intended purpose is correct

One or more of these aims should be identified and documented in the PMCF plan.

MDR Annex XIV, Part B, Section 6.2, specifies the required elements of a PMCF plan. Section 7 requires the manufacturer to analyze the findings of the PMCF and document the results in a PMCF evaluation report, which must be considered part of the clinical evaluation report and technical documentation. Section 8 requires the conclusions of the PMCF evaluation report to be taken into account in clinical evaluation and risk management. If the PMCF indicates the need for preventive and/or corrective measures, the manufacturer must implement them.

In addition, it is important to note that, from an MDR point of view, planning the conduct of any type of PMCF is within the post-market surveillance (PMS) system. This is because MDR Annex III, Technical Documentation on Post-Market Surveillance, Section 1.1, requires that the PMS plan include a PMCF plan or a justification of why a PMCF is not applicable.

## QMS and clinical investigations

### QMS and pre-market clinical investigations

---

It can be anticipated that most manufacturers will demonstrate compliance with the MDR by means of conformity assessment based on a QMS and assessment of technical documentation, as specified in MDR Annex IX. Section 2.2(c) requires that the documentation to be submitted for the assessment of the quality management system include an adequate description of: 'the procedures and techniques for monitoring, verifying, validating and controlling the design of the devices and the corresponding documentation as well as the data and records arising from those procedures and techniques.' Eight different elements that the procedures and techniques need to address are specified and, in brief, are:

- strategy for regulatory compliance
- identification of applicable GSPRs
- risk management
- clinical evaluation
- solutions for fulfilling the applicable specific requirements regarding design and construction
- solutions for fulfilling the applicable specific requirements regarding the information to be supplied with the device
- device identification procedures
- management of design or QMS changes

A pre-market clinical investigation is part of the design and development process because it is a design validation activity if it is intended to demonstrate that the device complies with regulatory requirements. Thus, the clinical investigation and its documentation should be managed within the company's QMS and be addressed during design and development planning, design and development reviews, and design validation.

The SOPs that may be helpful in conducting a clinical investigation are discussed later in this paper in the section, "Clinical investigation SOPs".

## QMS and PMCF investigations

---

The results of PMCF investigations will need to be documented in the PMCF evaluation report. They will also need to be considered in updating the CER, risk management, PMS report, periodic safety update report (PSUR), and for implantable devices and class III devices, the summary of safety and clinical performance (SSCP). The results of the PMCF investigation may also be linked to the need for corrective and preventive action, or in some cases, to validate a design change made in the post-market period.

For these reasons, manufacturers are encouraged to develop QMS procedures that will address these requirements and linkages to help ensure compliance with these interconnected regulatory requirements.



## Strategies for conducting successful clinical investigations

### Knowledgeable clinical affairs personnel

---

The importance of assigning responsibilities for managing clinical investigations, including PMCF investigations, to knowledgeable persons cannot be overemphasized. This is because clinical investigations are complex and the data generated expected to be ethically and scientifically valid, reliable, and robust. If not conducted properly, mistakes made could jeopardize the success of the project for which they are being conducted, such as, market entry or continued presence on the market.

For these reasons, clinical study personnel need to be aware not only of the regulatory requirements applicable to clinical study conduct, but also of the unique aspects of medical device clinical studies. For example, in contrast with many types of pharmaceutical studies, the success of many types of medical device clinical studies is heavily dependent on the quality and clarity of the CIP in describing how the medical device needs to be studied, the instructions for use, operating manual (where applicable), possible training needed, the expertise of the medical practitioner in the use of a particular medical device technology, or ability of a lay person to use the device.

Thus, it is strongly advised that clinical study management personnel have either the relevant experience or receive appropriate training in the conduct of medical device clinical studies before assuming responsibility for this important activity.

Where sponsors of medical device clinical studies lack adequate internal resources, outsourcing of various responsibilities may be advisable to ensure that unacceptable risks are avoided by involving personnel with insufficient experience.

## Clinical investigation SOPs

Sponsors of clinical investigations will need to develop clinical investigation-related SOPs to ensure compliance with the MDR, BS EN ISO 14155, any other applicable standards and requirements of other regulatory jurisdictions where a clinical investigation may be conducted. Any conflicting requirements should be identified and resolved. The SOPs should also take into consideration any official European guidance documents developed to aid compliance with the MDR. Where such guidance documents have not been developed and those used were developed to assist compliance with the Directives, any conflicts with the MDR need to be avoided.

The specific SOPs that a sponsor develops will depend upon the responsibilities of the sponsor in the development and management of the clinical investigation and whether any activities are outsourced. If all activities are managed in-house, clinical investigation SOPs should be sufficiently comprehensive to ensure compliance to applicable requirements, consistency and efficiency and the avoidance of costly mistakes and omissions throughout the entire clinical investigation process. For example, sponsors may wish to consider developing SOPs that address the following aspects of clinical investigation conduct:

- ✓ regulatory requirements applicable to location of clinical study sites (regional and local)
- ✓ development and amendment of CIP
- ✓ development of the investigator's brochure
- ✓ development of an informed consent form according to regional and national requirements
- ✓ clinical vendor qualification, selection, and management (e.g., CRO, central laboratory, other)
- ✓ compliance with regional and national requirements for ethics committee approval
- ✓ regulatory authority submission process
- ✓ conduct of the clinical investigation (responsibilities, procedures, staff qualifications, project-related training, other)

- ✓ clinical site qualification, selection, and management
- ✓ monitoring procedures
- ✓ adverse event reporting
- ✓ biostatistics, data collection and management
- ✓ document controls related to clinical studies, including management of records and study filing system
- ✓ data privacy requirements
- ✓ device accountability

It is important that these procedures are developed and controlled within the sponsor's QMS, where one exists.

Where certain activities of the clinical investigation are outsourced, the sponsor should ensure that the selected vendor is sufficiently qualified to provide the needed service. For example, vendors should be experienced in medical devices, operate under a QMS, have the necessary resources available to respond to client needs expeditiously, and other characteristics based on the needs of the clinical investigation project.

## Planning a medical device clinical investigation

---

### Elements of the planning process

A well-organized planning process provides a means of understanding what needs to be done and when, whether activities need to be sequential or can overlap to save time and who is responsible for the various activities.

It is evident that the way that this process can be managed varies. Table 1 provides an example of an approach for planning a clinical investigation to address activities before the study start, during study conduct and close-out activities. Other approaches may be effective and should be based on the purpose and type of clinical investigation, the medical device being studied, organization responsible for study conduct, and possibly other factors. The activities listed in Table 1 are not intended to be all inclusive. BS EN ISO 14155:2011 and revised ISO 14155 address clinical investigation planning in significant detail.

**Table 1:** Example of elements in a medical device clinical investigation plan

SET-UP PHASE	ENROLLMENT PHASE	CLOSE OUT PHASE
Project team setup	Training and site initiation	Site close out
Purpose & study design	Monitoring	Document archiving
Project management	Data collection and management	Statistics
Vendor selection	Adverse events & device deficiencies	Clinical study report
Development of CIP	Protocol deviations	Publications
Site selection	Device accountability	
Other regulatory/clinical documents	Audits	
Site agreements & EC/CA submissions		
Device release for clinical study		

### Purpose of the clinical investigation

As discussed previously, medical device clinical investigations are generally performed for regulatory purposes, but this is not always the case. Thus, the purpose for conducting the clinical investigation should be agreed at the beginning of the planning process as it will have a direct effect on the design of the study and clinical data that will need to be generated.

Regardless of the purpose, the clinical investigation will need to be designed to generate scientifically valid data suitable for the particular purpose. Section 9.3.1 of the European Guidelines on Clinical Evaluation (MEDDEV 2.7/1 Rev 4) provides helpful guidance on study design issues that can affect methodological quality and scientific validity such as the adequacy of the sample size and power calculation, endpoints, controls, and other design considerations.

## Project team

The persons participating in the project team should be identified, their roles and responsibilities identified, and their qualifications based on education, training, or experience. The specific roles will depend upon the sponsor's organization, the medical device, type of clinical investigation, and whether any roles are outsourced. Typical roles, however, include: the project manager, medical affairs function, product specialist, regulatory affairs function, biostatistician, data manager, and study monitor. Depending on the risks associated with the device, a Data Safety Monitoring Board or a Clinical Events Committee may be appointed. Other entities, such as centralized laboratories or an independent review committee to ensure homogeneous patient selection, may also be involved.

## Development of CIP

The importance of CIP document in the conduct of a medical device clinical investigation cannot be overstated. MDR Annex XV, Section 3 and Annex A of BS EN ISO 14155:2011 and Annex A of revised ISO 14155, specify the information that must be included in the CIP. If the clinical investigation is being conducted under the MDR, it is advisable to structure the CIP in accordance with the elements as listed in the MDR – however, the standard should be consulted when it provides additional detail for a CIP element.

The CIP should include clearly defined objectives and endpoints, intended purpose, patient population, and suitable inclusion and exclusion criteria, and any necessary medical, regulatory, and statistical input. The CIP should be a controlled document, ideally managed within an organization's QMS, where one has been established. At a minimum, both paper and electronic copies of revisions should be carefully checked to avoid mix-up. Regardless of the language in which the CIP is written – which is frequently English – it should be written to facilitate understanding with correct grammar and spelling. While this may seem obvious, these practices are not always followed, which can lead to unnecessary misunderstandings and delays in the project.

## Other study related documents

The planning phase needs to ensure the availability of other important study related documents, such as: the informed consent form used to record consent from study subjects to participate in the study; case report form (CRF) designed to record all information to be reported to the sponsor on each subject; IFU, which includes the intended purpose and any indications, contraindications, warnings and instructions for using the device; investigator's brochure (IB); and other documents, such as the statistical analysis plan, risk management documentation, insurance documentation and agreement between the sponsor and investigational site.

A strong correlation exists among many of these documents and the CIP, which means that inconsistencies among the documents should be avoided, such as variations in intended use statements in the CIP and other documents, inconsistent descriptions of contraindications or warnings and revisions of documents referenced in the CIP that differ from the revision level of the official documents.

## Site selection

The selection of the clinical study site(s) is a critical step in the planning of any clinical investigation and has a direct effect on study success. The selection of an inadequate site can lengthen the duration of a clinical study and in the worst case, lead to project failure. For this reason, study sites should be carefully chosen.

The recommended steps in selecting a study site are, at a minimum, the following:

- visit of the site by an expert in the device to be studied and a clinical study expert
- check of the availability of potentially eligible subjects and suitability of facilities and equipment
- assessment of the knowledge of study site personnel regarding GCPs, specifically pertaining to medical devices
- check of site resources, organization and skills
- assessment of ethics committee/investigational review board timelines

Too frequently, manufacturers sponsoring a clinical investigation have identified a key opinion leader (KOL), but not adequately evaluated the KOL's clinical site to ensure that it can enroll study subjects at an acceptable rate and has the necessary resources to provide the required services in a timely and compliant fashion.

## Monitoring

Monitoring is a quality-related tool to determine whether clinical investigation activities are performed as required and that deficiencies can be identified and corrected.

Recommendations for ensuring effective study monitoring include:

- ✓ following the procedures related to monitoring described in BS EN ISO 14155
- ✓ developing a Monitoring Plan, which will describe monitoring activities for a specific clinical investigation
- ✓ ensuring that monitoring is performed by a qualified study monitor (clinical research associate) with relevant education, training, and experience
- ✓ maintaining regular contact with study sites to ensure that study requirements are being met and any problems or deviations can be addressed in a timely fashion
- ✓ considering risk-based monitoring, where the monitoring plan for a clinical investigation is based on the reduction of risks that could affect the collection of critical data or performance of critical study activities
- ✓ exercising considerable care when monitoring remotely to ensure full compliance with regulatory requirements

## Data collection and management

Clinical data generated during a clinical investigation are usually collected on a case report form (CRF), which is a set of printed, optical or electronic documents designed for recording all information on each subject of a clinical investigation and reported to the sponsor as required by the CIP. Data management concerns the management of the collected data.

The MDR does not specify requirements concerning CRFs or data management other than requiring that data management be included in the CIP. Instead, the details regarding CRFs and data management are provided in BS EN ISO 14155:2011 and the revised standard.

## Cost considerations

Performing a clinical investigation can be the most expensive activity involved with CE-marking a new medical device or maintaining the CE mark. The cost of sponsoring a clinical investigation depends upon several factors, such as:

- complexity and duration of the study
- number of study subjects
- treatment and number of follow-up visits and type of checks made during the follow-up period
- number of countries involved
- number of study sites
- need for centralized laboratories
- whether study is managed in-house or by external vendors

Clearly, a determination of study costs is a critical element in the clinical investigation planning process. Thus, oversimplification of the process, which can lead to an underestimation of costs, should be avoided.



## Conclusion

---

A successful clinical investigation is one that generates scientifically valid clinical data, reaches medically and scientifically sound study conclusions and is completed within planned time frames. This means that sponsors, investigators, clinical monitors and others involved with the clinical investigation need to fully understand and comply with applicable regulatory requirements, standards and guidance documents. In addition, they should:

- ✔ ensure the involvement of qualified personnel in the planning and conduct of the clinical investigation
- ✔ ensure that appropriate QMS principles are followed throughout the clinical investigation process, including the development of relevant SOPs and control of clinical investigation-related documents
- ✔ ensure that an appropriate, compliant study design is developed
- ✔ carefully select clinical study sites based on factors that are important for the study, such as subject recruitment rate, resources and knowledge of GCPs – and not solely related to the presence of a KOL
- ✔ avoid underestimating the knowledge, qualified resources and activities needed to successfully complete a medical device clinical investigation.



## Further reading

---

- Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC
- Safety reporting in clinical investigations of medical devices under the Regulation (EU) 2017/745 (MDCG 2020-10/1)
- Clinical Investigation Summary Safety Report Form v1.0 (MDCG 2020-10/2)
- Guidelines on Clinical Investigation: A Guide for Manufacturers and Notified Bodies (MEDDEV 2.7/4, December 2010)
- Guidelines for Competent Authorities for Making a Validation/Assessment of a Clinical Investigation Application under Directives 93/42/EEC and 90/385/EEC (MEDDEV 2.7/2 Rev 2)
- Clinical Investigations: Serious Adverse Event Reporting Under Directives 90/385/EEC and 93/42/EEC (MEDDEV 2.7/3 Rev 3, May 2015)
- A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers Guidance for Industry (Food and Drug Administration Draft Guidance, March 2019)

## Author

---



**Maria E. Donawa, MD** is President of Donawa Lifescience, headquartered in Rome, Italy, with over 30 years' regulatory experience including six years with the US FDA in medical device regulation. In 1986, after moving to Rome, she founded two consecutively operating companies, which have become Donawa Lifescience (DL). DL provides clinical services to life science companies worldwide and US and European quality system and regulatory services. Dr Donawa has assisted a wide range of medical device and IVD medical device companies in complying with European requirements; is an active member of ISO TC 194 Working Group 4, responsible for the development and revision of ISO 14155, Clinical investigation of medical devices for human subjects – Good clinical practices; and is an observer in the Clinical Investigation and Evaluation subgroup of the Medical Devices Coordination Group (MDCG). For five years, Dr. Donawa served as a registered lead auditor, providing notified body auditing services to a German notified body. For over 25 years until closure of the publication, she was the regulatory columnist for *European Medical Device Technology*. Dr Donawa has US degrees in Pharmacy and Medicine and post-doctoral specialization in Clinical and Anatomical Pathology.

## Technical reviewers

### **Jane Edwards, Head of Communications, Global Product Management, BSI**

Jane holds a BSc in Chemistry and an MBA from Durham University. She has over 13 years' experience in the medical device industry, having previously worked for Coloplast in their ostomy and continence business. Jane's experience includes working within the pharmaceutical, chemical and telecoms industries for Glaxo Wellcome, ICI and Ericsson, allowing her to bring depth of knowledge from across many industries and technologies. Her current role in BSI allows her to work with technical reviewers across all disciplines ensuring that all BSI communications are accurate and relevant. She is a member of the European Medical Writers Association.

### **Danielle Giroud, Founder, CEO, World Medical Device Organization**

With over 30 years of experience, Ms Giroud is founder and senior faculty board member of the World Medical Device Organization (WMDO). Ms. Giroud is regarded as a recognized clinical research and regulatory expert within the medical device industry, having shared her extensive knowledge and experience with multi-national corporations and startup companies from around the globe. Since 2013, she founded MD-CLINICALS, a global CRO for medical devices with offices in Switzerland, Frankfurt, and Beijing. She is also currently convener for the expert group on clinical investigations; TC 194 WG4 for the ISO 14155 as well as liaison with the EU Commission – CIE (Clinical Investigation and Evaluation) task force.

**Eamonn Hoxey** is a technical author, trainer and consultant on a range of life science areas including regulatory compliance, quality management, sterility assurance and standards development. Eamonn worked for Johnson & Johnson (J&J) for 17 years in positions of increasing responsibility for Quality and Regulatory Compliance for medical devices, pharmaceuticals and consumer products. These included Vice President of Compliance, Vice President of Market Quality and Vice President of Quality & Compliance Strategic Programs, leading quality implementation for the EU medical devices regulation for J&J's Medical Devices companies. Prior to joining J&J, Eamonn spent 16 years with the UK Medical Devices Agency, including six years as Head of Device Technology and Safety. Eamonn is chair of CEN TC 204, Sterilization of medical devices, and chaired ISO TC 198, Sterilization of health care products, from 2011 to 2019. Eamonn is also a past chair of ISO TC 210, 'Quality management and related general aspects for medical devices', and the current chair of the Board of Directors of The Association for the Advancement of Medical Instrumentation (AAMI). He received the BSI Wolfe-Barry medal in 2016 for his contribution to standards development.

**Paul Sim** has worked in the healthcare industry for over 35 years, joined BSI in 2010 to lead the organization in Saudi Arabia where it had been designated as a Conformity Assessment Body. Later, he managed BSI's Unannounced Audits programme. Since October 2015, he has been working with both the Notified Body and Standards organizations looking at how best to use the knowledge, competencies and expertise in both. Previously he held senior RA/QA leadership positions at Spacelabs Healthcare, Teleflex Medical, Smiths Medical and Ohmeda (formerly BOC Group healthcare business). Paul is a member of the Association of British Healthcare Industries (ABHI) Technical Policy Group and Convenor of the ABHI ISO TC 210 Mirror Group. He is Convenor of the BSI Committee that monitors all of the work undertaken by ISO TC 210, and Convenor of the BSI Subcommittee dealing with quality systems. As UK Delegation Leader to ISO TC 210, he is also actively involved in the work of national, European and international standards' committees.

### **Paul Underwood, Medical Director, Boston Scientific Corporation**

Dr Paul Underwood, MD FACC, FSCAI is Medical Director for interventional cardiology/structural heart at Boston Scientific Corporation. He has over 20 years' experience in direct patient care and clinical research within multiple healthcare systems in the US, the Caribbean and Africa. Dr Underwood completed his medical studies at Mayo Clinic, Rochester, followed by cardiology training at the Cleveland Clinic. He is a Fellow of the American College of Cardiology and the Society for Cardiac Angiography and Intervention. He has also received certification from the Regulatory Affairs Professional Society and the Association of Clinical Research Professionals/Academy of Pharmaceutical Physicians and Investigators. His current responsibilities at Boston Scientific include clinical investigation design, safety monitoring and data analysis, clinical risk management and product development.

## **Published white papers**




---

- *The Proposed EU Regulations for Medical and In Vitro Diagnostic Devices: An Overview of the Likely Outcomes and Consequences for the Market*, Gert Bos and Erik Vollebregt
- *Generating Clinical Evaluation Reports – A Guide to Effectively Analysing Medical Device Safety and Performance*, Hassan Achakri, Peter Fennema and Itoro Udofia
- *Effective Post-Market Surveillance – Understanding and Conducting Vigilance and Post-Market Clinical Follow-up*, Ibim Tariah and Rebecca Pine
- *What You Need to Know About the FDA's UDI System Final Rule*, Jay Crowley and Amy Fowler
- *Engaging Stakeholders in the Home Medical Device Market: Delivering Personalized and Integrated Care*, Kristin Bayer, Laura Mitchell, Sharmila Gardner and Rebecca Pine
- *Negotiating the Innovation and Regulatory Conundrum*, Mike Schmidt and Jon Sherman
- *The Growing Role of Human Factors and Usability Engineering for Medical Devices: What's Required in the New Regulatory Landscape?* Bob North
- *ISO 13485: The Proposed Changes and What They Mean for You*, Bill Enos and Mark Swanson
- *The Differences and Similarities Between ISO 9001 and ISO 13485*, Mark Swanson
- *How to Prepare for and Implement the Upcoming MDR: Dos and Don'ts*, Gert Bos and Erik Vollebregt
- *How to Prepare for and Implement the Upcoming IVDR: Dos and Don'ts*, Gert Bos and Erik Vollebregt
- *Planning for Implementation of the European Union Medical Devices Regulations – Are You Prepared?* Eamonn Hoxey
- *Cybersecurity of Medical Devices*, Richard Piggin
- *The European Medical Devices Regulations – What Are the Requirements for Vigilance Reporting and Post-Market Surveillance?* Eamonn Hoxey

- *General Safety and Performance Requirements (Annex 1) in the New Medical Device Regulation – Comparison With the Essential Requirements of the Medical Device Directive and Active Implantable Device Directive*, Laurel Macomber and Alexandra Schroeder.
- *Do You Know the Requirements and Your Responsibilities for Medical Device Vigilance Reporting? – A Detailed Review on the Requirements of MDSAP Participating Countries in Comparison With the European Medical Device Regulation 2017/745*, Cait Gatt and Suzanne Halliday
- *Technical Documentation and Medical Device Regulation - A Guide for Manufacturers to Ensure Technical Documentation Complies With EU Medical Device Regulation 2017/745*, Dr Julianne Bobela, Dr Benjamin Frisch, Kim Rochat and Michael Maier
- *Nanotechnology – What Does the Future Look Like for the Medical Devices Industry?* Prof Peter J Dobson, with Dr Matthew O'Donnell
- *Developing and Maintaining a Quality Management System for IVDs*, Melissa Finocchio
- *Digital Maturity in an Age of Digital Excitement; Digital Maturity Goes Beyond Excitement to Quality*, Prof Harold Thimbleby
- *Recent Advancements in AI – Implications for Medical Device Technology and Certification*, Anil Anthony Bharath
- *Risk Management for Medical Devices and the New ISO 14971*, Jos van Vroonhoven
- *The Impact and Potential for 3D Printing and Bioprinting in the Medical Devices Industry*, Kenny Dalgarno
- *Sterilization: Regulatory requirements and supporting standards*, Eamonn Hoxey

## Forthcoming white papers

---

-  *The Convergence of pharma and medical devices*, Barbara Nasto and Jonathan Sutch (working title)
-  *Phthalates and endocrine disruptors* – Benjamin Seery (working title)
-  *Software as a medical device* – Pat Baird and Koen Cobbaert (working title)

## About BSI Group

---

BSI (British Standards Institution) is the business standards company that equips businesses with the necessary solutions to turn standards of best practice into habits of excellence. Formed in 1901, BSI was the world's first National Standards Body and a founding member of the International Organization for Standardization (ISO). Over a century later it continues to facilitate business improvement across the globe by helping its clients drive performance, manage risk and grow sustainably through the adoption of international management systems standards, many of which BSI originated. Renowned for its marks of excellence including the consumer recognized BSI Kitemark™, BSI's influence spans multiple sectors including aerospace, construction, energy, engineering, finance, healthcare, IT and retail. With over 70,000 clients in 150 countries, BSI is an organization whose standards inspire excellence across the globe.

BSI is keen to hear your views on this paper, or for further information please contact us here:  
[julia.helmsley@bsigroup.com](mailto:julia.helmsley@bsigroup.com)

This paper was published by BSI Standards Ltd.

For more information please visit:

<http://www.bsigroup.com/en-GB/our-services/medical-device-services/BSI-Medical-Devices-Whitepapers/>



**BSI National Standards Body**

389, Chiswick High Road  
London W4 4AL  
United Kingdom

T: +44 (0) 845 086 9001  
E: [cservices@bsigroup.com](mailto:cservices@bsigroup.com)  
[bsigroup.com](http://bsigroup.com)